High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding
Launched by CASA SOLLIEVO DELLA SOFFERENZA IRCCS · Sep 7, 2006
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
The recent Canadian consensus conference on the management of patients with non-variceal upper gastrointestinal bleeding recommends a high regimen of PPIs, consisting in a dosage of 80-mg bolus followed by the 8 mg/H infusion, as being superior to the standard dosage (40 mg twice daily by bolus injection) in conjunction with some type of endoscopic therapy. However, by pooling data fromm studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. As the previous conclusion became...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Consecutive patients admitted for upper gastrointestinal bleeding secondary to peptic ulcers that have been successfully treated with endoscopic therapy
- Exclusion Criteria:
- • Variceal esophageal bleeding
- • Concurrent PPI use
- • Moribund patients
About Casa Sollievo Della Sofferenza Irccs
Casa Sollievo della Sofferenza IRCCS is a renowned Italian research hospital and clinical trial sponsor dedicated to advancing medical science and improving patient care. Established with a commitment to high-quality research and innovative healthcare solutions, the institution integrates clinical practice with cutting-edge scientific research across various medical fields. As an IRCCS (Istituto di Ricovero e Cura a Carattere Scientifico), it plays a pivotal role in fostering collaboration among healthcare professionals, researchers, and industry partners to facilitate the development of new therapies and enhance treatment outcomes for patients. With a focus on ethical standards and patient safety, Casa Sollievo della Sofferenza IRCCS contributes significantly to the global medical community through its rigorous clinical trials and research initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Polla, Salerno, Italy
Caserta, , Italy
Como, , Italy
Cosenza, , Italy
Ivrea, , Italy
Piacenza, , Italy
San Giovanni Rotondo, , Italy
Torino, , Italy
Treviso, , Italy
Vasto, , Italy
Patients applied
Trial Officials
Andriulli Angelo, MD
Principal Investigator
Division of Gastroenterology, "Casa Sollievo della Sofferenza", San Giovanni Rotondo, ITALY
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials